Fundraising Fox
/Companies
Sign in

Third Arc Bio

Lower Gwynedd, US · Founded 2021 · Delaware corporation · 40 employees on LinkedIn · 12 known investors

Find your way into Third Arc Bio

Sign up to see every warm intro you have to Third Arc Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Third Arc Bio team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering. The company is led by a team with a track record of 35+ drug approvals.

BiotechMedical Devices

Founders & leadership

JEJoseph Erhardt
Joseph ErhardtChief Research & Development Officer
PL
Peter LebowitzExecutive

Board

AGArjun Goyal
Arjun GoyalBoard directorInvestment committee member at Tin Alley Ventures
OS
Otello StampacchiaBoard directorManaging Director at Omega Funds
FDFrancesco Draetta
Francesco DraettaBoard DirectorManaging Director at Omega Funds

Investors · 12

Andreessen Horowitzlisted by Andreessen HorowitzMenlo Park · $500K – $50M

How we know: a16z's portfolio · a partner's Signal profile · funding news · allsci.com · Not right? Tell us

Vida Ventureslisted by Vida VenturesLos Angeles

How we know: Vida Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

abrdn plcreportedEdinburgh

How we know: allsci.com · Not right? Tell us

Biotechnology Value FundreportedSan Francisco

How we know: allsci.com · Not right? Tell us

Foresite CapitalreportedWest Hollywood

How we know: funding news · Not right? Tell us

Hillhouse InvestmentreportedSingapore

How we know: allsci.com · Not right? Tell us

Omega FundsreportedBoston

How we know: funding news · allsci.com · Not right? Tell us

T. Rowe PricereportedBaltimore

How we know: allsci.com · Not right? Tell us

Also in the syndicate · 4

AbbVie VenturesAlderline GroupGalapagos NVLife Sciences at Goldman Sachs Alternatives

Funding

SEC filings, press & company announcements

$124.5M disclosed across 2 rounds · 2024–2026

▶$72.5MraisedAug 2024 · 32 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph ErhardtExecutive Officer
  • Arjun GoyalDirector
  • Otello StampacchiaDirector
  • Peter LebowitzExecutive Officer, Director
  • Francesco DraettaDirector
Offering amount
$165M
Amount sold
$72.5M
First sale
Jul 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

3T Biosciences3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets. The company creates therapeutic treatments targeting cancer and other difficult-to-treat diseases.
3Bar Biologics
ARTBIOARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue. The company covers the design, manufacture, and distribution of its therapies and builds on radiation research from the University of Oslo and Norway's Radium Hospital.

Companies working in the same space as Third Arc Bio.

In the news

Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfoliofinance.yahoo.com · Feb 2026Third Arc Bio Launches with Oversubscribed $165 Million Series A Financing to Deliver Superior Biologics for Solid Tumors and Inflammatory & Immunology (I&I) Diseasesprnewswire.com · Jul 2024

Frequently asked questions

What does Third Arc Bio do?
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering. The company is led by a team with a track record of 35+ drug approvals.
Who are Third Arc Bio's investors?
Third Arc Bio's investors include Andreessen Horowitz, Vida Ventures, abrdn plc, Biotechnology Value Fund, Foresite Capital, Hillhouse Investment, Omega Funds, T. Rowe Price.
How much funding has Third Arc Bio raised?
Third Arc Bio has disclosed $124.5M raised across 2 rounds.
Where is Third Arc Bio headquartered?
Third Arc Bio is headquartered in Lower Gwynedd, US.